The role of biologics in the treatment of giant cell arteritis

ABSTRACT: Introduction: Giant cell arteritis is a vasculitis of large and middle-sized arteries that affects individuals older than 50 years. Although glucocorticoids remain the mainstay in the treatment of this vasculitis, other drugs are often required to achieve clinical remission and allow gluco...

Descripción completa

Detalles Bibliográficos
Autores: González-Gay Mantecón, Miguel Ángel, Pina Murcia, Trinitario, Prieto Peña, Diana, Calderón Goercke, Mónica, Blanco Alonso, Ricardo|||0000-0003-2344-2285, Castañeda Sanz, Santos
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/16099
Acceso en línea:http://hdl.handle.net/10902/16099
Access Level:acceso abierto
Palabra clave:Abatacept
Anti-IL6-receptor tocilizumab
Giant cell (temporal) arteritis
Methotrexate
Prednisone
Relapses
id ES_10ae5a178ffe2c8e7166753ef024fa8b
oai_identifier_str oai:repositorio.unican.es:10902/16099
network_acronym_str ES
network_name_str España
repository_id_str
spelling The role of biologics in the treatment of giant cell arteritisGonzález-Gay Mantecón, Miguel ÁngelPina Murcia, TrinitarioPrieto Peña, DianaCalderón Goercke, MónicaBlanco Alonso, Ricardo|||0000-0003-2344-2285Castañeda Sanz, SantosAbataceptAnti-IL6-receptor tocilizumabGiant cell (temporal) arteritisMethotrexatePrednisoneRelapsesABSTRACT: Introduction: Giant cell arteritis is a vasculitis of large and middle-sized arteries that affects individuals older than 50 years. Although glucocorticoids remain the mainstay in the treatment of this vasculitis, other drugs are often required to achieve clinical remission and allow glucocorticoid discontinuation. Areas covered: The review summarizes the main biologic therapies used for the managements of GCA. Expert commentary: Although several biologic agents have been used in patients with GCA, the only biologic agent currently approved for this purpose is the recombinant humanized anti-IL-6 receptor antibody: tocilizumab. It has demonstrated efficacy to improve clinical symptoms, decrease the cumulative prednisone dose and reduce the frequency of relapses in clinical trials and real-life studies on patients with GCA. A trial showed that abatacept may be useful to maintain remission in GCA patients. An openlabel study suggested that ustekinumab could be useful for the treatment of patients with refractory GCA. However, further studies are required to confirm if both abatacept and ustekinumab are useful as an adjunctive therapy to reduce relapses or as a glucocorticoid sparing agent in GCA. Anakinra has been successfully used in a few patients with refractory GCA. In contrast, anti-tumor necrosis factor- α therapy yielded disappointing results in GCA.Taylor & FrancisUniversidad de Cantabria20192019-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttp://hdl.handle.net/10902/16099Expert Opinion on Biological Therapy, Volume 19, 2019 - Issue 1, 65-72reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/160992026-06-02T12:39:31Z
dc.title.none.fl_str_mv The role of biologics in the treatment of giant cell arteritis
title The role of biologics in the treatment of giant cell arteritis
spellingShingle The role of biologics in the treatment of giant cell arteritis
González-Gay Mantecón, Miguel Ángel
Abatacept
Anti-IL6-receptor tocilizumab
Giant cell (temporal) arteritis
Methotrexate
Prednisone
Relapses
title_short The role of biologics in the treatment of giant cell arteritis
title_full The role of biologics in the treatment of giant cell arteritis
title_fullStr The role of biologics in the treatment of giant cell arteritis
title_full_unstemmed The role of biologics in the treatment of giant cell arteritis
title_sort The role of biologics in the treatment of giant cell arteritis
dc.creator.none.fl_str_mv González-Gay Mantecón, Miguel Ángel
Pina Murcia, Trinitario
Prieto Peña, Diana
Calderón Goercke, Mónica
Blanco Alonso, Ricardo|||0000-0003-2344-2285
Castañeda Sanz, Santos
author González-Gay Mantecón, Miguel Ángel
author_facet González-Gay Mantecón, Miguel Ángel
Pina Murcia, Trinitario
Prieto Peña, Diana
Calderón Goercke, Mónica
Blanco Alonso, Ricardo|||0000-0003-2344-2285
Castañeda Sanz, Santos
author_role author
author2 Pina Murcia, Trinitario
Prieto Peña, Diana
Calderón Goercke, Mónica
Blanco Alonso, Ricardo|||0000-0003-2344-2285
Castañeda Sanz, Santos
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Abatacept
Anti-IL6-receptor tocilizumab
Giant cell (temporal) arteritis
Methotrexate
Prednisone
Relapses
topic Abatacept
Anti-IL6-receptor tocilizumab
Giant cell (temporal) arteritis
Methotrexate
Prednisone
Relapses
description ABSTRACT: Introduction: Giant cell arteritis is a vasculitis of large and middle-sized arteries that affects individuals older than 50 years. Although glucocorticoids remain the mainstay in the treatment of this vasculitis, other drugs are often required to achieve clinical remission and allow glucocorticoid discontinuation. Areas covered: The review summarizes the main biologic therapies used for the managements of GCA. Expert commentary: Although several biologic agents have been used in patients with GCA, the only biologic agent currently approved for this purpose is the recombinant humanized anti-IL-6 receptor antibody: tocilizumab. It has demonstrated efficacy to improve clinical symptoms, decrease the cumulative prednisone dose and reduce the frequency of relapses in clinical trials and real-life studies on patients with GCA. A trial showed that abatacept may be useful to maintain remission in GCA patients. An openlabel study suggested that ustekinumab could be useful for the treatment of patients with refractory GCA. However, further studies are required to confirm if both abatacept and ustekinumab are useful as an adjunctive therapy to reduce relapses or as a glucocorticoid sparing agent in GCA. Anakinra has been successfully used in a few patients with refractory GCA. In contrast, anti-tumor necrosis factor- α therapy yielded disappointing results in GCA.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10902/16099
url http://hdl.handle.net/10902/16099
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv Expert Opinion on Biological Therapy, Volume 19, 2019 - Issue 1, 65-72
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403523252224000
score 15.301603

Similares en LA Referencia